I-BET567

Research use only, not for human use.

I-BET567, a potent pan-BET inhibitor with oral activity, demonstrates pIC50 values of 6.9 and 7.2 for BRD4 BD1 and BD2, respectively. This compound has exhibited efficacy in mouse models of oncology and inflammation .

I-BET567 is a potent and orally active inhibitor of pan-BET candidate with pIC50s of 6.9 and 7.2 for BRD4 BD1 and BD2, respectively. I-BET567 has been demonstrated efficacy in mouse models of oncology and inflammation.

I-BET567 (compound 27) (72 hours; 1.5 nM-30 μM) effectively inhibites the proliferation of human NMC cell line 11060 in vitro with a mean gpIC50 6.2 (0.63 μM).Cell Viability Assay Cell Line:NMC line 11060 cells Concentration:1.5 nM-30 μM Incubation Time:72 hours Result:Significantly reduced cell growth.

I-BET567 (compound 27) (3, 10, and 30 mg/kg; p.o.; once daily for 20 days) leads to a significant reduction in tumor growth compared with vehicle controls at both 10 and 30 mg/kg.Assessment of Pharmacokinetics (PK) profile of I-BET567 following intravenous infusion and oral administration in male wistar han rat and beagle doga.a: Values are mean, n=3 unless otherwise stated. b: IV dose 1h infusion in DMSO and (10%, w/v) Kleptose HPB in saline (2%: 98% (v/v)). c: PO dose vehicle: 1%(w/v) methycellulose (400 cps) (aq). d: Mean n = 2.Animal Model:NMC 11060 xenograft mouse model (NOD/SCID mouse; bearing NMC 11060 cells) Dosage:3, 10, and 30 mg/kg Administration:p.o. (once daily for 20 days Result:Led to a significant reduction in tumor growth compared to vehicle controls at both 10 and 30 mg/kg.

——

Others

Other Targets

Others

——

——

1887237-54-8

359.81

C17H18ClN5O2

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (277.92 mM; Ultrasonic )

C[C@H]1C[C@@H](Nc2ncc(Cl)cn2)c2cc(ccc2N1C(C)=O)C(N)=O

——

(-20℃)

With Ice Pack

≥ 2 years